185 related articles for article (PubMed ID: 16406202)
1. Pituitary adenylate cyclase-activating peptide (PACAP): assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential.
Green BD; Irwin N; Flatt PR
Peptides; 2006 Jun; 27(6):1349-58. PubMed ID: 16406202
[TBL] [Abstract][Full Text] [Related]
2. Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice.
O'Harte FP; Mooney MH; Kelly CM; McKillop AM; Flatt PR
Regul Pept; 2001 Jan; 96(3):95-104. PubMed ID: 11111014
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR
Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice.
Ahrén B; Hughes TE
Endocrinology; 2005 Apr; 146(4):2055-9. PubMed ID: 15604213
[TBL] [Abstract][Full Text] [Related]
5. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
[TBL] [Abstract][Full Text] [Related]
6. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR
Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.
Green BD; Gault VA; Flatt PR; Harriott P; Greer B; O'Harte FP
Arch Biochem Biophys; 2004 Aug; 428(2):136-43. PubMed ID: 15246869
[TBL] [Abstract][Full Text] [Related]
8. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
Green BD; Gault VA; Mooney MH; Irwin N; Harriott P; Greer B; Bailey CJ; O'Harte FP; Flatt PR
Biol Chem; 2004 Feb; 385(2):169-77. PubMed ID: 15101559
[TBL] [Abstract][Full Text] [Related]
9. KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity.
Kim KR; Rhee SD; Kim HY; Jung WH; Yang SD; Kim SS; Ahn JH; Cheon HG
Eur J Pharmacol; 2005 Jul; 518(1):63-70. PubMed ID: 16106524
[TBL] [Abstract][Full Text] [Related]
10. A recombinant slow-release PACAP-derived peptide alleviates diabetes by promoting both insulin secretion and actions.
Ma Y; Fang S; Zhao S; Wang X; Wang D; Ma M; Luo T; Hong A
Biomaterials; 2015 May; 51():80-90. PubMed ID: 25771000
[TBL] [Abstract][Full Text] [Related]
11. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
[TBL] [Abstract][Full Text] [Related]
12. Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.
Green BD; Gault VA; Mooney MH; Irwin N; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
J Mol Endocrinol; 2003 Dec; 31(3):529-40. PubMed ID: 14664713
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
14. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
Moritoh Y; Takeuchi K; Hazama M
J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.
Mest HJ; Mentlein R
Diabetologia; 2005 Apr; 48(4):616-20. PubMed ID: 15770466
[TBL] [Abstract][Full Text] [Related]
16. Long-term administration of PACAP receptor antagonist, PACAP(6-27), impairs glucose tolerance and insulin sensitivity in obese diabetic ob/ob mice.
Green BD; Irwin N; Cassidy RS; Gault VA; Flatt PR
Peptides; 2006 Sep; 27(9):2343-9. PubMed ID: 16730098
[TBL] [Abstract][Full Text] [Related]
17. N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.
Green BD; Mooney MH; Gault VA; Irwin N; Bailey CJ; Harriott P; Greer B; O'Harte FP; Flatt PR
J Endocrinol; 2004 Mar; 180(3):379-88. PubMed ID: 15012592
[TBL] [Abstract][Full Text] [Related]
18. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.
Gault VA; Bhat VK; Irwin N; Flatt PR
J Biol Chem; 2013 Dec; 288(49):35581-91. PubMed ID: 24165127
[TBL] [Abstract][Full Text] [Related]
19. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38).
Zhu L; Tamvakopoulos C; Xie D; Dragovic J; Shen X; Fenyk-Melody JE; Schmidt K; Bagchi A; Griffin PR; Thornberry NA; Sinha Roy R
J Biol Chem; 2003 Jun; 278(25):22418-23. PubMed ID: 12690116
[TBL] [Abstract][Full Text] [Related]
20. Role of pituitary adenylate cyclase-activating polypeptide in the pancreatic endocrine system.
Ahrén B
Ann N Y Acad Sci; 2008 Nov; 1144():28-35. PubMed ID: 19076360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
